Can a diabetes drug slow kidney disease in type 1 diabetes?
Treatments studied
Part of Hormones & metabolism, Immune system & allergy, Kidney & urinary, Women’s health & pregnancy clinical trials.
This study tests whether a medication called an SGLT2 inhibitor (canagliflozin-like) can help slow kidney disease in people with type 1 diabetes. It may help protect your kidneys if you already have protein in your urine and reduced kidney function.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 or older with type 1 diabetes (diagnosed before age 40, started insulin within a year).
- You have protein in your urine (UACR > 100 mg/g on at least two of three recent morning samples).
- Your kidney function (eGFR) is between 25 and 75 ml/min/1.73m2.
- You have been on a stable dose of an ACE inhibitor or ARB (blood pressure meds) for at least 4 weeks.
- You cannot have had diabetic ketoacidosis (except at diagnosis), very high blood sugar (HbA1c > 85), or low carbohydrate diet.
- You are not pregnant, breastfeeding, planning pregnancy, or on SGLT2 inhibitors recently.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether sotagliflozin (a pill that helps control blood sugar and protects the kidneys) can slow down kidney function decline in people with type 1 diabetes and diabetic kidney disease. You may qualify if you have had type 1 diabetes for at least 8 years, have moderate kidney damage, and are on standard treatments.
This study tests how a drug called canagliflozin (an SGLT2 inhibitor) affects kidney function in people with type 2 diabetes. It involves two kidney biopsies to see how the drug works inside your kidneys, aiming to better protect kidney health.
This Phase 2 study compares tofogliflozin to metformin to see how well they reduce urine albumin levels (a marker of kidney stress) in people with diabetic kidney disease. You might benefit if your type 2 diabetes is affecting your kidneys despite standard blood-pressure medicines.
This study tests if ganagliflozin, a once-daily pill, can slow down kidney damage in people with type 2 diabetes and chronic kidney disease. It may help protect your kidneys and manage blood sugar.
This study tests whether a common diabetes medication (SGLT2 inhibitor) can help people with autosomal dominant polycystic kidney disease (ADPKD) maintain kidney function longer. If you have fast-growing kidney cysts and are between 18 and 60 years old, this trial may be an option.
This study tests whether SGLT2 inhibitors (a type of diabetes drug that also helps kidneys) can help patients with acute kidney disease. It may be an option if you have diabetes or chronic kidney disease along with acute kidney problems.
Hear when a new Nephropathy trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.